Osimertinib in advanced EGFR T790M-positive non-small-cell lung cancer: the clinical impact of AURA3

Patients with advanced epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) receive first-line therapy with an EGFR tyrosine kinase inhibitor (TKI). This treatment strategy is based on the results of several phase 3 trials which have demonstrated superiority of EGFR TKIs over first-line chemotherapy in terms of progression-free survival and quality of life in these patients (1). This strategy also mandates EGFR mutation analysis in patients with advanced NSCLC, particularly in those with adenocarcinomas (2). A study in the real-world setting in Central European countries, where lung cancer incidence rates are high, confirmed that EGFR mutation testing has been implemented and that patients with advanced EGFR mutation-positive NSCLC preferentially receive first-line therapy with EGFR TKIs in routine clinical practice (3).